Methods of treating ocular diseases using derivatives of lipoic acid
AssigneeEncore Health, LLC
InventorsWilliam Garner, Margaret Garner, George Minno, David Gooden
Life of this patent
Estimating the term…
Abstract
Dithiol compounds and derivatives thereof are disclosed. The agents are useful for treating an ocular disease, especially presbyopia and cataract. Also provided are methods of treating an ocular disease, the methods comprising administering to a subject an active agent and an adjunctive agent.
Claims35
A method of treating presbyopia comprising administering to a subject a compound having a structure of Formula I-NC, or a pharmaceutically acceptable salt thereof:
- wherein at least one of X and Y is sulfur, and the other is sulfur, selenium, or a sulfonic group;
- R19 is substituted or unsubstituted alkylene;
- R20, R21, R30, and R31 are each independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted, heteroalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
- wherein R30 and R31 may optionally be joined together or together form a single bond;
- Z is N or O;
- and m is 0 or 1, wherein if Z is O, then m is 0, and if Z is N, then m is 1,
- and wherein the compound is not lipoic acid.
The method of claim wherein the compound has a R configuration.
A pharmaceutical composition comprising a compound having a structure of Formula V or Formula V-NC, or a pharmaceutically acceptable salt thereof:
- wherein at least one of X and Y is sulfur, and the other is sulfur, selenium, or a sulfonic group;
- R19 is substituted or unsubstituted alkylene;
- R30 and R31 are each independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
- wherein R30 and R31 may optionally be joined together or together form a single bond;
- R21 is a choline substituent;
- and a pharmaceutically acceptable excipient.
A pharmaceutical composition comprising a compound having a structure of Formula I or a pharmaceutically acceptable salt thereof:
- wherein both X and Y are sulfur;
- R19 is unsubstituted C4 alkylene;
- R20 and R21 are each independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
- Z is N or O;
- and m is 0 or 1, wherein if Z is O then m is 0, and if Z is N, then m is 1,
- and wherein the compound is not lipoic acid;
- and
- a pharmaceutically acceptable excipient.
A method of treating an ocular disease, comprising administering to a subject an active ingredient and choline.
A method of treating an ocular disease, comprising administering to a subject an active ingredient of lipoic acid and an adjunctive agent.
Dependencies are inferred from the claim text.